Its been a tough few years for investors in this big-cap biotech, but signals are emerging that better days are ahead.
A new study is planned that could someday reshape colon cancer screenings.
Here's what you should know about this fast-growing cannabis company following its latest quarterly financial results.
Sales slipped from the fourth quarter, but there's still a lot to like about this company.
The company's still struggling to transition from clinical stage to commercial stage, but it's making progress.
First-quarter financial results are failing to spark investor optimism on concerns over cash burn.
This big-cap biotech has a problem or two on its hands.
GW Pharmaceuticals reported surging sales last quarter, but investors ought to be aware of a lot more than that.
This drugmaker's cannabidiol formulation could become more widely used following positive phase 3 trial results in tuberous sclerosis complex.
The company is one step closer to securing an OK for its new cholesterol-busting drug.
Anemic second-quarter financials have investors reining in their expectations.
These two disruptive companies reported crazy-good top-line growth, but only one can be the winner.
The insulin pump maker reported better-than-expected first-quarter financials and issued a rosier outlook for 2019.
These stocks play a role in our lives every day and that could make them perfect for portfolios.
If you're hunting pot stocks with the best chance of turning rising sales into shareholder profit, you ought to consider these stocks.
The clinical-stage biopharmaceutical company is on track to file for FDA approval of its first drug, trilaciclib.
If you're hunting for top growth stocks to add to long-term portfolios, you ought to consider these fast-growing companies.
These marijuana stocks could be about to see their revenue skyrocket.
If you don't own these high-income stocks yet, you might want to consider buying them now.
A patient death raises questions ahead of a key FDA decision next month.